# Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

> **NCT06355310** · PHASE2 · RECRUITING · sponsor: **Justin Ryder** · enrollment: 40 (estimated)

## Conditions studied

- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT06355310
- **Lead sponsor:** Justin Ryder
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06355310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06355310, "Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06355310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*